Ray Furey, J.D.

Senior Vice President, Chief Compliance Officer

Ray Furey, J.D. serves as senior vice president and chief compliance officer at Turning Point Therapeutics. He is responsible for overseeing the company’s compliance with various laws and regulations impacting the business.

With over 30 years of pharmaceutical experience, Mr. Furey has led global compliance and enterprise risk management programs at several public companies. He most recently served as senior vice president and chief compliance officer at Portola Pharmaceuticals which was acquired by Alexion in 2020. Prior to joining Portola Pharmaceuticals, Mr. Furey was senior vice president, chief compliance officer and an executive team member at Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals which Mallinckrodt acquired in 2014. He also served as compliance officer at OSI Pharmaceuticals which was acquired by Astellas in 2010. Prior to that, he spent 17 years at Genentech in various roles, including Compliance, Commercial Operations, Finance, Regulatory Affairs and Manufacturing.

Mr. Furey received his J.D. from Fordham University School of Law in New York City and his B.A. in Natural Sciences from Trinity College Dublin in Ireland. He is a member of the New York State and U.S. Supreme Court Bars and is registered with the California State Bar.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb